Recently, Margetuximab, a new generation mAb, has been approved in combination with chemotherapy for the treatment of patients with metastatic HER2+ BC, with results obtained through SOPHIA clinical trial (Table 1) [22,50,51,52,53]. The gene discussed is ERBB2; the disease is breast cancer.